CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer

por Yamamoto, N, Murakami, H, Hayashi, H, Fujisaka, Y, Hirashima, T, Takeda, K, Satouchi, M, Miyoshi, K, Akinaga, S, Takahashi, T, Nakagawa, K
Publicado 2013

Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib

por Satouchi, M, Negoro, S, Funada, Y, Urata, Y, Shimada, T, Yoshimura, S, Kotani, Y, Sakuma, T, Watanabe, H, Adachi, S, Takada, Y, Yatabe, Y, Mitsudomi, T
Publicado 2007

A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician’s choice in patients with advanced non-small cell lung...

por Katakami, N., Felip, E., Spigel, D. R., Kim, J.-H., Olivo, M., Guo, M., Nokihara, H., Yang, J. C.-H., Iannotti, N., Satouchi, M., Barlesi, F.
Publicado 2017

Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer...

por Hotta, K., Hida, T., Nokihara, H., Morise, M., Kim, Y.H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Kumagai, T., Watanabe, S., Goto, K., Satouchi, M., Kozuki, T., Shukuya, T., Nakagawa, K., Mitsudomi, T., Yamamoto, N., Asakawa, T., Yoshimoto, T., Takata, S., Tamura, T.
Publicado 2022